Masimo (NASDAQ: MASI) announced today that its Founder,
Chairman, and CEO, Joe Kiani, has been honored by the
Ibero-American Society of Neonatology (SIBEN) at its 17th Annual
Congress (this year held virtually) with the Award for Improvement
of Neonatal Health in Latin America. In her award presentation,
SIBEN Scientific Group member Dr. Susana Rodríguez praised Mr.
Kiani for his lifelong dedication to improving newborn care.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201109005531/en/
Joe Kiani (Photo: Business Wire)
SIBEN, founded in 2004, is dedicated to improving newborn care
throughout Latin America—where 15 babies die every hour, with 60%
of those who die before their first birthday dying during the first
28 days after birth.1 SIBEN is comprised of more than 2,000
healthcare professionals associated with neonatal care.
Dr. Rodríguez noted that Mr. Kiani’s commitment to neonatal care
started with the invention, in 1995, of Masimo Signal Extraction
Technology®, or SET®, pulse oximetry, whose breakthrough ability to
measure through motion and low perfusion led to remarkable
improvements in neonatal care. In particular, use of SET® has
played a key role in reducing the rate of neonatal blindness
(retinopathy of prematurity). In 2003, Dr. Augusto Sola (Managing
Director of SIBEN) and colleagues showed that using a new protocol
with Masimo SET®, clinicians reduced ROP to nearly zero over five
years.2 A later study showed that the protocol’s success depended
on SET® technology, as the same protocol with a competing pulse
oximeter did not reduce ROP.3 Today, SET® pulse oximetry is used to
monitor more than 200 millions patients each year,4 and has been
shown, among other benefits, to help improve critical congenital
heart disease (CCHD) screening in newborns.5
Continuing, Dr. Rodríguez highlighted how Mr. Kiani’s creativity
and vision have led to many additional medical advancements in the
years since, with Masimo, which recently celebrated its 31st
anniversary, remaining at the forefront of global medical
innovation. Mr. Kiani has long championed the importance of patient
safety, and in 2013 created The Patient Safety Movement Foundation,
dedicated to achieving zero preventable deaths by 2030. To date,
more than 4,700 hospitals in 50 countries have committed to this
goal—and an estimated 93,000 lives are being saved annually.6 Among
other honors and awards, Mr. Kiani has been named SafeCare’s Person
of the Year and one of “50 Experts in Patient Safety” by Becker’s
Hospital Review. He received an Honorary Doctorate of Science from
Chapman University, and is an Honorary member of the Mexican
Academy of Surgery.
In his acceptance speech, Mr. Kiani said, “Thank you to all the
neonatologists and the care providers around neonates. There’s so
much apathy, and I think that’s the biggest hurdle to improving
patient care – but not with neonatologists and neonatal nurses. You
have never stopped amazing me with how much you care for our
babies, your patients. I also want to thank SIBEN for the
incredible work you’re doing to bridge the gap between knowledge
and what’s practiced. You know better than I that what’s common
practice is unfortunately not always best practice – and your work
– to educate, educate, educate – is critical in bridging that gap,
so more babies get the best care possible. I want to thank Dr.
Susana Rodríguez and the board of SIBEN for honoring me with this
meaningful award.”
Kiani continued, “I want to tell you how blessed I feel to have
friends like Mohammad Diab and Dr. Augusto Sola, who helped me with
a great innovation, not only to innovate our measure-through-motion
pulse oximetry, but to innovate a way to use it to help so many
babies. That gift, which these two incredible friends have given
me, has allowed me to feel fulfilled, and even though I know I’m
just a speck in time and in space, at least we’ve been together, my
dear friends, a useful speck, that may have given birth and
happiness to more specks to enjoy the joy and pain of life, which
is precious. Thank you again for this incredible award. Thanks for
encouraging me to try harder, and for encouraging others to try
harder, to do the right thing.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.7 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,3 improve CCHD screening in newborns,5 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.8-11 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,4 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S.
News and World Report Best Hospitals Honor Roll.12 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- SIBEN data on file.
- Chow LC, Wright KW, Sola A. Can Changes in Clinical Practice
Decrease the Incidence of Severe Retinopathy of Prematurity in Very
Low Birth Weight Infants? Pediatrics. 2003 Feb;111(2):339-45.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- Masimo data on file.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Patient Safety Movement Foundation data on file.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SET®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SET®, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005531/en/
Media Contact: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024